EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Efficacy of Remdesivir and Neutralizing Monoclonal Antibodies in Monotherapy or Combination Therapy in Reducing the Risk of Disease Progression in Elderly or Immunocompromised Hosts Hospitalized for COVID-19: A Single Center Retrospective Study

Davide Fiore Bavaro iD, Lucia Diella, Alessandra Belati, Giuliana Metrangolo, Laura De Santis, Vito Spada, Michele Camporeale, Angelo Dargenio, Gaetano Brindicci iD, Flavia Balena, Deborah Fiordelisi, Fabio Signorile und 15 weitere

Viruses · 2023

DOI: 10.3390/v15051199 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Viruses, 2023. Verfasst von Davide Fiore Bavaro und 26 weiteren Autor:innen. Beteiligte Einrichtung: Clinic of Infectious Diseases, Department of Precision and Regenerative Medicine and Ionian Area, University of Bari, Piazza G. Cesare 11, 70124 Bari…. Hauptthemen laut MEDLINE: COVID-19. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Next Generation EU-MUR PNRR Extended Partnership initiative on Emerging Infectious Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Remdesivir (REM) and monoclonal antibodies (mAbs) could alleviate severe COVID-19 in at-risk outpatients. However, data on their use in hospitalized patients, particularly in elderly or immunocompromised hosts, are lacking.

Methods

All consecutive patients hospitalized with COVID-19 at our unit from 1 July 2021 to 15 March 2022 were retrospectively enrolled. The primary outcome was the progression to severe COVID-19 (P/F < 200). Descriptive statistics, a Cox univariate–multivariate model, and an inverse probability treatment-weighted (IPTW) analysis were performed.

Results

Overall, 331 subjects were included; their median (q1–q3) age was 71 (51–80) years, and they were males in 52% of the cases. Of them, 78 (23%) developed severe COVID-19. All-cause in-hospital mortality was 14%; it was higher in those with disease progression (36% vs. 7%, p < 0.001). REM and mAbs resulted in a 7% (95%CI = 3–11%) and 14% (95%CI = 3–25%) reduction in the risk of severe COVID-19, respectively, after adjusting the analysis with the IPTW. In addition, by evaluating only immunocompromised hosts, the combination of REM and mAbs was associated with a significantly lower incidence of severe COVID-19 (aHR = 0.06, 95%CI = 0.02–0.77) when compared with monotherapy.

Conclusions

REM and mAbs may reduce the risk of COVID-19 progression in hospitalized patients. Importantly, in immunocompromised hosts, the combination of mAbs and REM may be beneficial.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19AgedMaleHumansAged, 80 and overFemaleRetrospective StudiesCOVID-19 Drug TreatmentAntibodies, MonoclonalAntibodies, NeutralizingImmunocompromised HostDisease ProgressionAdenosine MonophosphateAlanine

Stichwörter der Autor:innen

COVID-19 progressionCOVID-19 therapySARS-CoV-2antiviralscombination therapyelderlyimmunocompromised hostsmonoclonal antibodiesremdesivirsevere COVID-19sotrovimab

Substanzen

Antibodies, MonoclonalAntibodies, NeutralizingremdesivirAdenosine MonophosphateAlanine

Autor:innen und Institutionen

  • Clinic of Infectious Diseases, Department of Precision and Regenerative Medicine and Ionian Area, University of Bari, Piazza G. Cesare 11, 70124 Bari, Italy.
  • Hematology Unit, IRCCS Istituto Tumori "Giovanni Paolo II", 70124 Bari, Italy.
  • Unit of Hematology and Stem Cell Transplantation, AOUC Policlinic, 70124 Bari, Italy.
  • Nephrology Dialysis and Transplantation Unit, Department of Precision and Regenerative Medicine and Ionian Area, University of Bari, 70124 Bari, Italy.
  • Section of Gastroenterology, Department of Emergency and Organ Transplantation, University of Bari, 70124 Bari, Italy.
  • Hospital Pharmacy Department, University Hospital of Bari, 70124 Bari, Italy.

ORCID-Profile: Davide Fiore Bavaro, Gaetano Brindicci, Carla Minoia, Francesco Di Gennaro, Pellegrino Musto, Alfredo Di Leo, Loreto Gesualdo

Förderung

  • Next Generation EU-MUR PNRR Extended Partnership initiative on Emerging Infectious Diseases

Zitieren

APA

Bavaro, D. F., Diella, L., Belati, A., Metrangolo, G., De Santis, L., Spada, V., Camporeale, M., Dargenio, A., Brindicci, G., Balena, F., Fiordelisi, D., Signorile, F., Loseto, G., Pasciolla, C., Minoia, C., Attolico, I., Perrone, T., Simone, S., Rendina, M., …, & Saracino, A. (2023). Efficacy of Remdesivir and Neutralizing Monoclonal Antibodies in Monotherapy or Combination Therapy in Reducing the Risk of Disease Progression in Elderly or Immunocompromised Hosts Hospitalized for COVID-19: A Single Center Retrospective Study. Viruses. https://doi.org/10.3390/v15051199

Vancouver

Bavaro DF, Diella L, Belati A, Metrangolo G, De Santis L, Spada V, et al. Efficacy of Remdesivir and Neutralizing Monoclonal Antibodies in Monotherapy or Combination Therapy in Reducing the Risk of Disease Progression in Elderly or Immunocompromised Hosts Hospitalized for COVID-19: A Single Center Retrospective Study. Viruses. 2023. doi:10.3390/v15051199

BibTeX
@article{Bavaro2023,
  author = {Bavaro, Davide Fiore and Diella, Lucia and Belati, Alessandra and Metrangolo, Giuliana and De Santis, Laura and Spada, Vito and Camporeale, Michele and Dargenio, Angelo and Brindicci, Gaetano and Balena, Flavia and Fiordelisi, Deborah and Signorile, Fabio and Loseto, Giacomo and Pasciolla, Crescenza and Minoia, Carla and Attolico, Immacolata and Perrone, Tommasina and Simone, Simona and Rendina, Maria and Giovine, Nicoletta and Di Gennaro, Francesco and Musto, Pellegrino and Guarini, Attilio and Di Leo, Alfredo and Gesualdo, Loreto and Dell'Aera, Maria and Saracino, Annalisa},
  title = {Efficacy of Remdesivir and Neutralizing Monoclonal Antibodies in Monotherapy or Combination Therapy in Reducing the Risk of Disease Progression in Elderly or Immunocompromised Hosts Hospitalized for COVID-19: A Single Center Retrospective Study},
  journal = {Viruses},
  year = {2023},
  doi = {10.3390/v15051199}
}
Kostenlos starten →